S&P 500   4,967.23
DOW   37,986.40
QQQ   417.41
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.41
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.41
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
S&P 500   4,967.23
DOW   37,986.40
QQQ   417.41
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Intuitive Surgical Leads the Robotic Surgery Movement
Stock market today: Wall Street eyes corporate earnings after last week's Big Tech selloff
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

$1.39
-0.01 (-0.71%)
(As of 04/19/2024 06:55 PM ET)
Today's Range
$1.39
$1.41
50-Day Range
$1.28
$1.57
52-Week Range
$1.26
$2.66
Volume
17,600 shs
Average Volume
54,275 shs
Market Capitalization
$68.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MNOV stock logo

About MediciNova Stock (NASDAQ:MNOV)

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV Stock Price History

MNOV Stock News Headlines

StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Medicinova Inc
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MNOV
Employees
13
Year Founded
2000

Profitability

Net Income
$-8,560,000.00
Pretax Margin
-856.80%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.27 per share

Miscellaneous

Free Float
40,757,000
Market Cap
$68.18 million
Optionable
Optionable
Beta
0.75

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 74)
    Ph.D., Co-Founder, President, CEO & Executive Director
    Comp: $933.05k
  • Dr. Kazuko Matsuda M.D. (Age 58)
    M.P.H., Ph.D., Chief Medical Officer & Director
    Comp: $653.65k
  • Mr. Jason J. Kruger CPA (Age 46)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 59)
    Ph.D., Chief Business Officer
  • Mr. John O'Neil CPA
    Controller

MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed in 2024?

MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV stock has decreased by 7.3% and is now trading at $1.39.
View the best growth stocks for 2024 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04.

What other stocks do shareholders of MediciNova own?
How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNOV) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners